ALLRMEDIUM SIGNALFINANCIAL10-K

ALLR significantly reduced operating losses while implementing enhanced cybersecurity governance protocols and maintaining adequate cash reserves.

The company demonstrated meaningful progress in cost management with substantially reduced operating losses and improved cash flow efficiency. However, the ongoing burn rate and declining cash position from $19.5M to $14.7M requires careful monitoring of runway sustainability.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

ALLR showed notable operational improvement with substantially reduced losses and meaningfully better operating cash flow performance. The company maintained a solid balance sheet with current assets of $17.9M against current liabilities of only $8.4M, though total assets declined modestly across the board. Capital expenditures dropped dramatically from $298K to $8K, reflecting a more disciplined spending approach while preserving cash for core operations.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-97.3%
$298K$8K

Capex reduced 97.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
+54.2%
-$24.5M-$11.2M

Net income grew 54.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+53.7%
-$27.2M-$12.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Cash & Equivalents
Balance Sheet
-24.8%
$19.5M$14.7M

Cash decreased 24.8% — monitor burn rate and upcoming capital needs.

Total Liabilities
Balance Sheet
-22.2%
$10.8M$8.4M

Liabilities reduced 22.2% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-22.2%
$10.8M$8.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-19.8%
$22.3M$17.9M

Current assets declined 19.8% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-19.4%
$22.6M$18.3M

Total assets contracted 19.4% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-16.8%
$11.8M$9.8M

Equity decreased 16.8% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Cash Flow
Cash Flow
+14.6%
-$17.4M-$14.8M

Operating cash flow grew 14.6% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
false --12-31 FY 2025 true true true It is expected that IT governance and cybersecurity will be included in our quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer.
Senior management regularly meets with and provides periodic briefings to our board of directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
It is expected that IT governance and cybersecurity will be included in our quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer.
Senior management regularly meets with and provides periodic briefings to our board of directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.
It is expected that IT governance and cybersecurity will be included in our quarterly management review meetings under the supervision of our senior leadership, including our Chief Executive Officer and Chief Financial Officer.
+7 more — sign up free →
REMOVED
As of March 31, 2025, there were 17,014,737 shares of the registrant s common stock outstanding.
References in this Annual Report to our therapeutic candidate, our therapeutic candidate, stenoparib, or stenoparib refer to our sole current therapeutic candidate, stenoparib.
In the second half of 2023, we seated two new independent directors to our board of directors, Laura E.
Jensen is a co-founder of Allarity and has extensive experience not only with the core DRP platform technology but also with capital fund raising.
In the second half of 2024, we added a new Chief Financial Officer, Mr.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →